Skip to Main Content

Advertisement

Skip Nav Destination

Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models

Cancer Res (2015) 75 (15_Supplement): 2690.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Maria Teresa Masucci
  • Maria Letizia Motti
  • Michele Minopoli
  • Gioconda Di Carluccio
  • Maria Vincenza Carriero
International Journal of Molecular Sciences (2023) 24 (7): 6026.
  • Animesh Pardanani
American Journal of Hematology (2021) 96 (4): 508.
  • Thais Cristina Mendonça Nogueira
  • Marcus Vinicius Nora de Souza
Bioorganic & Medicinal Chemistry (2021) 46: 116340.
  • Tingting Lu
  • Cheng Chen
  • Aoli Wang
  • Zongru Jiang
  • Ziping Qi
  • Zhenquan Hu
  • Chen Hu
  • Feiyang Liu
  • Wenliang Wang
  • Hong Wu
  • Beilei Wang
  • Li Wang
  • Shuang Qi
  • Jiaxin Wu
  • Wenchao Wang
  • Jun Tang
  • Hezhong Yan
  • Mingfeng Bai
  • Qingsong Liu
  • Jing Liu
Cancer Letters (2019) 447: 105.
  • Animesh Pardanani
American Journal of Hematology (2019) 94 (3): 363.
  • Siham Bibi
  • Michel Arock
Immunology and Allergy Clinics of North America (2018) 38 (3): 527.
  • César Serrano
  • Suzanne George
  • Claudia Valverde
  • David Olivares
  • Alfonso García-Valverde
  • Cristina Suárez
  • Rafael Morales-Barrera
  • Joan Carles
Targeted Oncology (2017) 12 (3): 277.
  • Vineela Kasireddy
  • Margaret von Mehren
Expert Opinion on Emerging Drugs (2017) 22 (4): 317.
  • Vaia Florou
  • Breelyn A Wilky
  • Jonathan C Trent
Future Oncology (2017) 13 (24): 2183.
  • Animesh Pardanani
American Journal of Hematology (2016) 91 (11): 1146.
Close Modal

or Create an Account

Close Modal
Close Modal